S-3 GROUP

Lobbying for ORCHARD THERAPEUTICS NORTH AMERICA · Biotech company

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2026 · Massachusetts · House · Senate · $60,000.00 income · posted Apr 17, 2026

Lobbying activity 2

Budget/Appropriations

Issues related to funding for newborn screenings for metachromatic leukodystrophy

Medical/Disease Research/Clinical Labs

Issues related to funding for newborn screenings for metachromatic leukodystrophy

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.